{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:19:53Z","timestamp":1790831993914,"version":"4.1.0"},"reference-count":188,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigaci\u00f3n (AEI) and Regional Development European Funds (FEDER, European Union)","award":["RED2018-102723-T"],"award-info":[{"award-number":["RED2018-102723-T"]}]},{"name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades (MCIU) Plan Estatal de I+D+I 2018, Agencia Estatal de Investigaci\u00f3n (AEI) and Regional Development European Funds (FEDER, European Union)","award":["RTI2018-097455-B-I00 (MCIU\/AEI\/FEDER, UE"],"award-info":[{"award-number":["RTI2018-097455-B-I00 (MCIU\/AEI\/FEDER, UE"]}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00275"],"award-info":[{"award-number":["CB16\/12\/00275"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Consejer\u00eda de Salud of the Junta de Andaluc\u00eda","award":["PI-0397-2017"],"award-info":[{"award-number":["PI-0397-2017"]}]},{"name":"Consejeria of Econom\u00eda, Conocimiento, Empresas y Universidad of the Junta de Andalucia","award":["P18-RT-2501"],"award-info":[{"award-number":["P18-RT-2501"]}]},{"name":"Fundaci\u00f3n AECC","award":["AECC"],"award-info":[{"award-number":["AECC"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Ovarian cancer is the most lethal gynecological malignancy due to its late detection and high recurrence rate. Resistance to conventional platinum-based therapies and metastasis are attributed to a population of cells within tumors called cancer stem cells, which possess stem-like features and are able to recapitulate new tumors. Recent studies have deepened the understanding of the biology of ovarian cancer stem cells and their special properties and have identified multiple markers and signaling pathways responsible for their self-renewal abilities. Targeting cancer stem cells represents the most promising strategy for overcoming therapy resistance and reducing mortality in ovarian cancer, but further efforts must be made to improve our understanding of the mechanisms involved in therapy resistance. In this review, we summarize our current knowledge about ovarian cancer stem cells, their involvement in metastasis and their interactions with the tumor microenvironment; we also discuss the therapeutic approaches that are being developed to target them to prevent tumor relapse.<\/jats:p>","DOI":"10.3390\/cells9061402","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T03:32:21Z","timestamp":1591327941000},"page":"1402","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer"],"prefix":"10.3390","volume":"9","author":[{"given":"Sandra","family":"Mu\u00f1oz-Galv\u00e1n","sequence":"first","affiliation":[{"name":"Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Roc\u00edo, Universidad de Sevilla, Consejo Superior de Investigaciones Cient\u00edficas, Avda. Manuel Siurot s\/n, 41013 Seville, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4357-3979","authenticated-orcid":false,"given":"Amancio","family":"Carnero","sequence":"additional","affiliation":[{"name":"Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Roc\u00edo, Universidad de Sevilla, Consejo Superior de Investigaciones Cient\u00edficas, Avda. Manuel Siurot s\/n, 41013 Seville, Spain"},{"name":"CIBERONC, Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"Ca Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: First-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2011.01.026","article-title":"Chemotherapy in epithelial ovarian cancer","volume":"303","author":"Pignata","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc3597","article-title":"Unravelling cancer stem cell potential","volume":"13","author":"Beck","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1111\/febs.13023","article-title":"Cancer stem cells--important players in tumor therapy resistance","volume":"281","author":"Colak","year":"2014","journal-title":"Febs J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.07.001","article-title":"The cancer stem-cell signaling network and resistance to therapy","volume":"49","author":"Carnero","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1158\/1078-0432.CCR-10-2538","article-title":"Cancer stem cells and chemosensitivity","volume":"17","author":"Vigneri","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/onc.2010.215","article-title":"EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer","volume":"29","author":"Singh","year":"2010","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","article-title":"Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant","volume":"102","author":"Hu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation--a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc.2016.113","article-title":"The disparate origins of ovarian cancers: Pathogenesis and prevention strategies","volume":"17","author":"Karnezis","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1200\/JCO.2008.18.1107","article-title":"New insights into the pathogenesis of serous ovarian cancer and its clinical impact","volume":"26","author":"Levanon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ygyno.2018.08.005","article-title":"Surgical prevention strategies in ovarian cancer","volume":"151","author":"Mallen","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"934261","DOI":"10.1155\/2014\/934261","article-title":"Recent concepts of ovarian carcinogenesis: Type I and type II","volume":"2014","author":"Koshiyama","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kim, J., Park, E.Y., Kim, O., Schilder, J.M., Coffey, D.M., Cho, C.H., and Bast, R.C. (2018). Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel), 10.","DOI":"10.3390\/cancers10110433"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhang, W., Klinkebiel, D., Barger, C.J., Pandey, S., Guda, C., Miller, A., Akers, S.N., Odunsi, K., and Karpf, A.R. (2020). Global DNA Hypomethylation in Epithelial Ovarian Cancer: Passive Demethylation and Association with Genomic Instability. Cancers (Basel), 12.","DOI":"10.1101\/2020.01.22.20018374"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8961","DOI":"10.1158\/0008-5472.CAN-05-1187","article-title":"CpG island methylation of DNA damage response genes in advanced ovarian cancer","volume":"65","author":"Teodoridis","year":"2005","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","article-title":"Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2013.06.014","article-title":"Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo","volume":"339","author":"Orsulic","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncb2717","article-title":"Cancer stem cells: The challenges ahead","volume":"15","author":"Medema","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ahmed, N., Kadife, E., Raza, A., Short, M., Jubinsky, P.T., and Kannourakis, G. (2020). Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 9.","DOI":"10.3390\/cells9030719"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-017-0638-3","article-title":"Ovarian cancer stem cells: Still an elusive entity?","volume":"16","author":"Lupia","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.0805012105","article-title":"Normal ovarian surface epithelial label-retaining cells exhibit stem\/progenitor cell characteristics","volume":"105","author":"Szotek","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11979","article-title":"Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche","volume":"495","author":"Hwang","year":"2013","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","article-title":"Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness","volume":"103","author":"Szotek","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4161\/cc.8.1.7533","article-title":"Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance","volume":"8","author":"Alvero","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/01443615.2017.1336753","article-title":"CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma","volume":"38","author":"Bartakova","year":"2018","journal-title":"J. Obs. Gynaecol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Foster, B.M., Zaidi, D., Young, T.R., Mobley, M.E., and Kerr, B.A. (2018). CD117\/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines, 6.","DOI":"10.1101\/256099"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.yexmp.2011.06.005","article-title":"Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome","volume":"91","author":"Luo","year":"2011","journal-title":"Exp. Mol. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2012.290","article-title":"c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/beta-catenin-ATP-binding cassette G2 signaling","volume":"32","author":"Chau","year":"2013","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/onc.2010.35","article-title":"CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells","volume":"29","author":"Gao","year":"2010","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-14-0607","article-title":"CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis","volume":"14","author":"Wu","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.4086","article-title":"CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges","volume":"229","author":"Fargeas","year":"2013","journal-title":"J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/stem.236","article-title":"CD133 expression defines a tumor initiating cell population in primary human ovarian cancer","volume":"27","author":"Curley","year":"2009","journal-title":"Stem Cells"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/onc.2008.374","article-title":"Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells","volume":"28","author":"Baba","year":"2009","journal-title":"Oncogene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1073\/pnas.1005529108","article-title":"Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells","volume":"108","author":"Stewart","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.stem.2007.08.014","article-title":"ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome","volume":"1","author":"Ginestier","year":"2007","journal-title":"Cell Stem Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1158\/1535-7163.MCT-10-0563","article-title":"Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer","volume":"9","author":"Landen","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1158\/0008-5472.CAN-10-3175","article-title":"Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival","volume":"71","author":"Silva","year":"2011","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/onc.2014.178","article-title":"beta-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids","volume":"34","author":"Condello","year":"2015","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1158\/0008-5472.CAN-17-0366","article-title":"NFkappaB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH(+) Cancer Stem-like Cells","volume":"77","author":"House","year":"2017","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.biocel.2016.07.017","article-title":"Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines","volume":"78","author":"Januchowski","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Meng, E., Mitra, A., Tripathi, K., Finan, M.A., Scalici, J., McClellan, S., Madeira da Silva, L., Reed, E., Shevde, L.A., and Palle, K. (2014). ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107142"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature05284","article-title":"A protein interaction network for pluripotency of embryonic stem cells","volume":"444","author":"Wang","year":"2006","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"a008128","DOI":"10.1101\/cshperspect.a008128","article-title":"Pluripotency in the embryo and in culture","volume":"4","author":"Nichols","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.bbagrm.2015.03.006","article-title":"Establishing pluripotency in early development","volume":"1849","author":"Paranjpe","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Thomson","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/onc.2009.500","article-title":"Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer","volume":"29","author":"Peng","year":"2010","journal-title":"Oncogene"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13402-013-0142-8","article-title":"The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients","volume":"36","author":"Di","year":"2013","journal-title":"Cell. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-1130-z","article-title":"Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness","volume":"19","author":"Perez","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/cas.13186","article-title":"SOX2 is required to maintain cancer stem cells in ovarian cancer","volume":"108","author":"Wen","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ncb2976","article-title":"Oncogenic roles of EMT-inducing transcription factors","volume":"16","author":"Puisieux","year":"2014","journal-title":"Nat. Cell Biol"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: The mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1073\/pnas.1102454108","article-title":"Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state","volume":"108","author":"Chaffer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cell.2013.06.005","article-title":"Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity","volume":"154","author":"Chaffer","year":"2013","journal-title":"Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/stem.154","article-title":"Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells","volume":"27","author":"Kurrey","year":"2009","journal-title":"Stem Cells"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massague","year":"2016","journal-title":"Nature"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","article-title":"Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: A potential role in I.p. metastatic dissemination","volume":"69","author":"Moss","year":"2009","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2018.02.001","article-title":"Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization","volume":"33","author":"Schild","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1158\/1535-7163.MCT-14-0579","article-title":"Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78","volume":"14","author":"Mo","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_82","first-page":"1108","article-title":"Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites","volume":"8","author":"Milliken","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0002-9440(10)65406-5","article-title":"CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells","volume":"154","author":"Lessan","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_84","first-page":"1228","article-title":"In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: A novel role for CD44 in the process of peritoneal implantation","volume":"57","author":"Strobel","year":"1997","journal-title":"Cancer Res."},{"key":"ref_85","first-page":"2105","article-title":"Mesothelial cells facilitate cancer stemlike properties in spheroids of ovarian cancer cells","volume":"40","author":"Shishido","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: Rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrc3820","article-title":"Challenges in circulating tumour cell research","volume":"14","author":"Pantel","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/ncb2048","article-title":"Wnt activity defines colon cancer stem cells and is regulated by the microenvironment","volume":"12","author":"Vermeulen","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s41388-018-0527-2","article-title":"Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment","volume":"38","author":"Perez","year":"2019","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrc2618","article-title":"Microenvironmental regulation of metastasis","volume":"9","author":"Joyce","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","article-title":"An evolving story of the metastatic voyage of ovarian cancer cells: Cellular and molecular orchestration of the adipose-rich metastatic microenvironment","volume":"38","author":"Motohara","year":"2019","journal-title":"Oncogene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","article-title":"Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers","volume":"8","author":"Pearce","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/onc.2016.256","article-title":"Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4","volume":"36","author":"Harjes","year":"2017","journal-title":"Oncogene"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-14-0445","article-title":"Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer","volume":"20","author":"Tucker","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ccell.2016.06.020","article-title":"Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche","volume":"30","author":"Miranda","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1158\/1078-0432.CCR-11-1916","article-title":"Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors","volume":"18","author":"Klopp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/0008-5472.CAN-14-1337","article-title":"Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells","volume":"75","author":"Caneba","year":"2015","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1073\/pnas.0900244106","article-title":"The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells","volume":"106","author":"Coffelt","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1172\/JCI45273","article-title":"Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production","volume":"121","author":"McLean","year":"2011","journal-title":"J. Clin. Invest."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and Significance of the Pre-metastatic Niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-12-0206","article-title":"MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer","volume":"2","author":"Mitra","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2011.08.005","article-title":"Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts","volume":"123","author":"Cho","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/stemcells.2007-0742","article-title":"Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells","volume":"26","author":"Jeon","year":"2008","journal-title":"Stem Cells"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","article-title":"TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment","volume":"73","author":"Yeung","year":"2013","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/bjc.2017.356","article-title":"TAMeless traitors: Macrophages in cancer progression and metastasis","volume":"117","author":"Aras","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2007-02-072587","article-title":"Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells","volume":"110","author":"Duluc","year":"2007","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI87316","article-title":"Extracellular vesicles: Masters of intercellular communication and potential clinical interventions","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-014-1710-4","article-title":"Tumor-derived exosomes in oncogenic reprogramming and cancer progression","volume":"72","author":"Saleem","year":"2015","journal-title":"Cell Mol. Life Sci"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"21493","DOI":"10.1002\/jcp.28905","article-title":"The potential role of exosomes derived from ovarian cancer cells for diagnostic and therapeutic approaches","volume":"234","author":"Yang","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(02)09552-1","article-title":"Malignant effusions and immunogenic tumour-derived exosomes","volume":"360","author":"Andre","year":"2002","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/2326-6066.CIR-17-0113","article-title":"Exosomes Associated with Human Ovarian Tumors Harbor a Reversible Checkpoint of T-cell Responses","volume":"6","author":"Shenoy","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjc.6602316","article-title":"Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects","volume":"92","author":"Taylor","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"43076","DOI":"10.18632\/oncotarget.9246","article-title":"Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Gobbo, J., Marcion, G., Cordonnier, M., Dias, A.M.M., Pernet, N., Hammann, A., Richaud, S., Mjahed, H., Isambert, N., and Clausse, V. (2016). Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv330"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41467-018-04695-7","article-title":"Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface","volume":"9","author":"Tang","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/1078-0432.CCR-04-1688","article-title":"Cleavage of L1 in exosomes and apoptotic membrane vesicles released from ovarian carcinoma cells","volume":"11","author":"Gutwein","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","article-title":"Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells","volume":"15","author":"Nakamura","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-16-0714","article-title":"Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells","volume":"76","author":"Kanlikilicer","year":"2016","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1535-7163.MCT-05-0102","article-title":"Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells","volume":"4","author":"Safaei","year":"2005","journal-title":"Mol. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"11150","DOI":"10.1038\/ncomms11150","article-title":"Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1","volume":"7","author":"Co","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1038\/s41388-017-0106-y","article-title":"Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype","volume":"37","author":"Akhter","year":"2018","journal-title":"Oncogene"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","article-title":"Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: A novel mechanism linking STAT3\/Rab proteins","volume":"37","author":"Dorayappan","year":"2018","journal-title":"Oncogene"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"Ca Cancer J. Clin."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"Ca Cancer J. Clin."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(18)30343-7","article-title":"Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT Ov-21): A placebo-controlled, phase 3 randomised trial","volume":"19","author":"Friedlander","year":"2018","journal-title":"Lancet. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1470-2045(18)30333-4","article-title":"Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16\/NOVA): Results from a double-blind, phase 3, randomised controlled trial","volume":"19","author":"Oza","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/1541-7786.MCR-18-0594","article-title":"PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells","volume":"17","author":"Bellio","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/stem.2929","article-title":"Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy","volume":"37","author":"Jarrar","year":"2019","journal-title":"Stem Cells"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cdd.2013.136","article-title":"Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells","volume":"21","author":"Venere","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.stem.2018.11.017","article-title":"Targeting Cancer Stemness in the Clinic: From Hype to Hope","volume":"24","author":"Saygin","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Zong, X., and Nephew, K.P. (2019). Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. Cancers (Basel), 11.","DOI":"10.3390\/cancers11070934"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/IGC.0b013e3182a1d023","article-title":"Effects and mechanisms of anti-CD44 monoclonal antibody A3D8 on proliferation and apoptosis of sphere-forming cells with stemness from human ovarian cancer","volume":"23","author":"Du","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1158\/1078-0432.CCR-13-1536","article-title":"Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: An optimal delivery of siRNA and anticancer drug","volume":"19","author":"Shah","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1158\/1078-0432.CCR-09-2317","article-title":"Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides","volume":"15","author":"Slomiany","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group Study","volume":"26","author":"Schilder","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.celrep.2019.02.032","article-title":"A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells","volume":"26","author":"Chefetz","year":"2019","journal-title":"Cell Rep."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Nwani, N.G., Condello, S., Wang, Y., Swetzig, W.M., Barber, E., Hurley, T., and Matei, D. (2019). A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. Cancers (Basel), 11.","DOI":"10.3390\/cancers11040502"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.trecan.2017.04.004","article-title":"Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity","volume":"3","author":"Wainwright","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1158\/1078-0432.CCR-17-3055","article-title":"A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses","volume":"24","author":"Matei","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1158\/0008-5472.CAN-14-1022","article-title":"Epigenetic targeting of ovarian cancer stem cells","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/onc.2016.337","article-title":"Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer","volume":"36","author":"Witt","year":"2017","journal-title":"Oncogene"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-17-0437","article-title":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","volume":"17","author":"Jones","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1073\/pnas.1422165112","article-title":"An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma","volume":"112","author":"Baratta","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1158\/0008-5472.CAN-16-0854","article-title":"BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer","volume":"76","author":"Yokoyama","year":"2016","journal-title":"Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Roy, L., and Cowden Dahl, K.D. (2018). Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer?. Cancers (Basel), 10.","DOI":"10.20944\/preprints201806.0262.v1"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrclinonc.2010.196","article-title":"Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways","volume":"8","author":"Takebe","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13046-019-1245-5","article-title":"New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools","volume":"38","author":"Navas","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1158\/0008-5472.CAN-05-3610","article-title":"Notch3 gene amplification in ovarian cancer","volume":"66","author":"Park","year":"2006","journal-title":"Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-08-0001","article-title":"Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion","volume":"68","author":"Choi","year":"2008","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"E2939","DOI":"10.1073\/pnas.1206400109","article-title":"Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy","volume":"109","author":"McAuliffe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2015.03.005","article-title":"A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia","volume":"137","author":"Wilson","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2015.12.011","article-title":"Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752","volume":"140","author":"Chen","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-14-2797","article-title":"A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors","volume":"21","author":"Chiorean","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1038\/ncomms9989","article-title":"The Notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids","volume":"6","author":"Kessler","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/ncb3000","article-title":"Lgr5 marks stem\/progenitor cells in ovary and tubal epithelia","volume":"16","author":"Ng","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Anastas","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.08.005","article-title":"Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28","volume":"146","author":"Le","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/carcin\/bgn230","article-title":"Aberrant activation of hedgehog signaling pathway in ovarian cancers: Effect on prognosis, cell invasion and differentiation","volume":"30","author":"Liao","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1158\/1078-0432.CCR-08-1414","article-title":"Role of hedgehog signaling in ovarian cancer","volume":"14","author":"Bhattacharya","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_174","first-page":"797","article-title":"Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells","volume":"39","author":"Ray","year":"2011","journal-title":"Int J. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1038\/onc.2011.610","article-title":"Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair","volume":"31","author":"Kudo","year":"2012","journal-title":"Oncogene"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1158\/0008-5472.CAN-10-1242","article-title":"Hippo pathway effector Yap is an ovarian cancer oncogene","volume":"70","author":"Hall","year":"2010","journal-title":"Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/onc.2011.8","article-title":"The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene","volume":"30","author":"Zhang","year":"2011","journal-title":"Oncogene"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/onc.2015.288","article-title":"YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells","volume":"35","author":"Hua","year":"2016","journal-title":"Oncogene"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"He, C., Lv, X., Huang, C., Hua, G., Ma, B., Chen, X., Angeletti, P.C., Dong, J., Zhou, J., and Wang, Z. (2019). YAP1-LATS2 feedback loop dictates senescent or malignant cell fate to maintain tissue homeostasis. Embo. Rep., 20.","DOI":"10.15252\/embr.201744948"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Xia, Y., Zhang, Y.L., Yu, C., Chang, T., and Fan, H.Y. (2014). YAP\/TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0109575"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cpr.12038","article-title":"Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway","volume":"46","author":"Luo","year":"2013","journal-title":"Cell Prolif."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/stem.2279","article-title":"Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism","volume":"34","author":"Seo","year":"2016","journal-title":"Stem Cells"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00404-014-3377-3","article-title":"PI3K\/AKT\/mTOR signaling pathway as a therapeutic target for ovarian cancer","volume":"290","author":"Li","year":"2014","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/0008-5472.CAN-17-1671","article-title":"STAT3\/PIAS3 Levels Serve as \u201cEarly Signature\u201d Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube","volume":"78","author":"Saini","year":"2018","journal-title":"Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Abubaker, K., Luwor, R.B., Zhu, H., McNally, O., Quinn, M.A., Burns, C.J., Thompson, E.W., Findlay, J.K., and Ahmed, N. (2014). Inhibition of the JAK2\/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-317"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Rinkenbaugh, A.L., and Baldwin, A.S. (2016). The NF-kappaB Pathway and Cancer Stem Cells. Cells, 5.","DOI":"10.3390\/cells5020016"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-tumor heterogeneity from a cancer stem cell perspective","volume":"16","author":"Prasetyanti","year":"2017","journal-title":"Mol. Cancer"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1402\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:45Z","timestamp":1760175345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/6\/1402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":188,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["cells9061402"],"URL":"https:\/\/doi.org\/10.3390\/cells9061402","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}